Imagene Partners with Oracle to Launch CanvOI on Oracle Cloud Infrastructure

Rhea-AI Summary

Oracle and Imagene have launched CanvOI, a state-of-the-art pan-cancer foundation model running on Oracle Cloud Infrastructure (OCI). CanvOI is designed to decode cancer from biopsy images and drive cancer research forward. The model, with 1.1 billion parameters, was pre-trained on over 630,000 tissue images from more than 100 sites, covering 40+ major body organs and tissue types.

CanvOI aims to improve cancer diagnosis and treatment by providing valuable oncology intelligence. It outperforms leading digital pathology foundation models in tasks such as predicting treatment responses, discovering biomarkers, and assessing disease prognosis. The model leverages OCI Supercluster and OCI AI Infrastructure for AI inference computation and large-scale data processing.

Positive

• Partnership with Oracle provides access to powerful cloud infrastructure for AI computation
• CanvOI outperforms leading foundation models in digital pathology
• Pre-trained on a diverse dataset of 630,000+ tissue images from 100+ sites
• Covers 40+ major body organs and tissue types
• Potential to improve cancer diagnosis and treatment methods

Negative

• None.

Insights

Tech Expert

The launch of CanvOI on Oracle Cloud Infrastructure represents a significant leap in AI-driven oncology research. This 1.1 billion parameter foundation model leverages OCI's advanced capabilities, including Supercluster and AI Infrastructure technology, to process vast amounts of medical imaging data efficiently.

The model's ability to analyze 630,000+ tissue images from over 100 sites and 40+ major body organs showcases its comprehensive scope. Its performance in various cancer-related tasks, especially with minimal labeled data, addresses a important challenge in biomedical research. This could accelerate discoveries and potentially revolutionize cancer diagnosis and treatment methodologies.

The collaboration between Imagene and Oracle demonstrates the growing trend of specialized AI models being deployed on robust cloud infrastructures, enabling scalability and high-performance computing essential for complex medical research.

Medical Research Analyst

CanvOI's introduction marks a pivotal moment in digital pathology and oncology research. Its pan-cancer approach, covering a wide range of organs and tissue types, offers unprecedented potential for comprehensive cancer analysis. The model's ability to predict treatment responses, discover biomarkers and assess prognosis could significantly enhance personalized medicine approaches in oncology.

The OISuite platform, built on CanvOI, democratizes access to advanced AI tools for researchers and diagnostic developers. This could accelerate the pace of discoveries by allowing experts to focus on scientific questions rather than AI technicalities. However, it's important to note that while AI models like CanvOI show promise, their integration into clinical practice will require rigorous validation and regulatory approval processes to ensure patient safety and efficacy.

Market Research Analyst

This partnership between Imagene and Oracle signifies a strategic move in the rapidly growing AI healthcare market. The global digital pathology market, valued at $926.9 million in 2021, is projected to reach $2.2 billion by 2028, with AI integration being a key driver. Oracle's involvement positions it strongly in this high-growth sector, leveraging its cloud infrastructure expertise.

For Imagene, this collaboration provides access to Oracle's extensive resources and global reach, potentially accelerating market penetration. The OISuite platform could create a new revenue stream through subscription or usage-based models. However, competition in this space is intensifying, with major tech and healthcare companies investing heavily in AI-driven diagnostic tools. Success will depend on CanvOI's performance in real-world applications and its ability to integrate seamlessly into existing healthcare workflows.

CanvOI Oncology Intelligence (OI) foundation model is designed to decode cancer from biopsy images and drive cancer research forward

MIAMI and AUSTIN, Texas, Sept. 10, 2024 /PRNewswire/ -- Oracle and Imagene, a pioneer in AI-based precision oncology, today announced CanvOI, a state-of-the-art pan-cancer foundation model designed to facilitate innovative research and development in the digital pathology and oncology space. Running on Oracle Cloud Infrastructure (OCI), CanvOI captures the complex features and patterns within biopsy images, providing valuable oncology intelligence that could improve the way cancer is diagnosed and treated around the world.

CanvOI delivers a robust vision data backbone for the development of downstream applications in oncology research, including predicting treatment responses, discovering biomarkers, assessing disease prognosis, and identifying pathological features with state-of-the-art results, outperforming leading foundation models built for digital pathology.

For AI inference computation and to process data at scale, Imagene partnered with Oracle to run CanvOI on OCI, taking advantage of OCI Supercluster and OCI AI Infrastructure technology.

"To transform cancer research, Imagene did what countless other leading AI startups have done – it turned to Oracle's Gen2 AI infrastructure, which delivers the scale and performance required to power the world's largest AI models and help solve humanity's most difficult challenges," said Larry Ellison, Oracle Chairman and CTO. "With CanvOI running on Oracle Cloud Infrastructure, Oracle and Imagene are providing scientists with new weapons in the fight against mankind's deadliest adversary, cancer."

"The next decade holds immense potential for breakthroughs in cancer research driven by Artificial Intelligence," said Dean Bitan, Co-founder and CEO, Imagene. "We designed CanvOI to inspire researchers to dare to explore beyond. This is a pivotal milestone in the fight against this complex and devastating disease. By opening doors for innovative research, we aim to fundamentally change the future of cancer care."

CanvOI, a 1.1 billion parameters foundation model, was pre-trained on a diverse dataset including more than 630,000 tissue images from over 100 sites, covering more than 40 major body organs and tissue types. By applying a new approach to digital pathology foundation models and pushing computational demands differently, CanvOI has achieved industry-leading performance across various cancer-related tasks. Its ability to perform effectively, even with minimal labeled data, is crucial in the biomedical space, where data availability can be challenging.

CanvOI is the cornerstone of Imagene's new OISuite, a platform that supports researchers and diagnostics developers to explore a wide range of questions to conduct in-depth research independently, alleviating the need for AI expertise and extensive data acquisition. OISuite enables rapid discoveries while delivering the highest standards of data privacy and security.

"CanvOI transforms our approach to healthcare and disease understanding," said Dr. David Agus, Founding Director and Co-CEO, Ellison Institute of Technology and Imagene board member. "By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. EIT is committed to leveraging CanvOI to propel groundbreaking innovations in our research that improve patient lives. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition."

Additional Resources

• CanvOI scientific paper, including benchmarks

About Imagene
Imagene is a pioneering company in AI-based precision oncology, dedicated to decoding cancer using biopsy images. Our mission is to unlock the power of Oncology Intelligence to transform cancer research and diagnostics. Imagene's OISuite, powered by our state-of-the-art pan-cancer vision foundation model, enables the development of diverse applications and accelerates discoveries in oncology. LungOI, our AI-based NSCLC multi-gene test, was developed using our foundation model and provides rapid biomarker profiling, facilitating informed clinical decisions.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/imagene-partners-with-oracle-to-launch-canvoi-on-oracle-cloud-infrastructure-302242989.html

SOURCE Oracle

FAQ

What is CanvOI and how does it relate to Oracle (ORCL)?

CanvOI is a pan-cancer foundation model developed by Imagene in partnership with Oracle. It runs on Oracle Cloud Infrastructure (OCI) and uses OCI Supercluster and AI Infrastructure for computation and data processing.

How many parameters does the CanvOI model have?

The CanvOI model has 1.1 billion parameters.

What is the dataset size used to train CanvOI?

CanvOI was pre-trained on a diverse dataset including more than 630,000 tissue images from over 100 sites.

How can CanvOI benefit cancer research?

CanvOI can benefit cancer research by providing valuable oncology intelligence for predicting treatment responses, discovering biomarkers, assessing disease prognosis, and identifying pathological features with state-of-the-art results.